Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham Tepezza Prior Auth | OpenPaye…
    Ask Trek AI about this page
    CurrentMass General Brigham Health PlanPolicy N/A

    Tepezza (teprotumumab-trbw) Continuation Therapy

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and continuation coverage for Tepezza under the medical benefit for adults with thyroid eye disease, including documentation, clinical criteria, dosing limits, and reauthorization requirements.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyTepezza (teprotumumab-trbw) Continuation Therapy
    Policy CodePolicy N/A
    Change TypeMaterial coverage criteria update
    Effective DateJan 4, 202746d
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit clinical rationale for Tepezza instead of Lumvoa and confirm the member has no history of Lumvoa treatment.
    SourceLink
    POLICY UPDATE CHANGES

    Clinical rationale for using Tepezza instead of Lumvoa was added as a coverage criterion.

    Confirmation that the member has no history of treatment with Lumvoa was added as a coverage criterion.

    The policy was updated with formatting and reference changes during the November 2026 review.

    8 dosesMaximum doses in one course of therapy

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 months
    Maximum duration of one course
    1 courseMaximum courses per lifetime
    18 yearsMinimum member age
    90 daysNew-to-plan documentation window

    Coverage Criteria

    New-to-plan members

    For members new to the plan, submit documentation of current treatment with the requested drug.

    New-to-plan continuation documentation: Member has a coverage effective date of less than or equal to 90 days and is currently receiving the requested drug.Coverage effective date <= 90 days

    Treatment obtained as samples or through manufacturer patient assistance programs does not qualify.

    Standard authorization

    Authorization may be granted when all of the following criteria are met.

    Standard Tepezza authorization criteria

    • Clinical diagnosis and age: Member has a diagnosis of thyroid eye disease and is at least 18 years of age.Age >= 18 years
    • ONE of

      • Prescriber is an endocrinologist.
      • Prescriber is an ophthalmologist.
      • Consult notes from an endocrinologist or ophthalmologist are provided.
    • ONE of

      • Member has an inadequate response to glucocorticoids.
      • Member has an adverse reaction to glucocorticoids.
      • Member has a contraindication to glucocorticoids.
      • Documentation supports that the member is not a candidate for corticosteroids.

        See Appendix A.

    • Product selection and treatment history: Clinical rationale is provided for use of Tepezza instead of Lumvoa, and the member has no history of treatment with Lumvoa.
    • Dosing: Appropriate dosing is requested and the member's weight is provided.Weight required

    Continuation within initial course

    Reauthorization by a physician may be granted for members who have not completed 6 months or 8 doses of treatment.

    Continuation within initial course: Member has not completed the initial course of Tepezza.Has not completed 6 months (8 doses) of treatment

    Approvals are limited to a maximum of 8 doses over 6 months for one course of therapy per lifetime.

    Additional-course review

    Additional courses beyond the initial course are evaluated case by case for medical necessity.

    Repeat-course medical necessity factors

    • Disease severity: Severity of disease supports repeat treatment.
    • Prior response: Response to prior courses of therapy supports repeat treatment.
    • Prior adherence: Adherence to prior courses supports repeat treatment.
    • Failed alternatives: Alternative treatment trials have failed or are insufficient.

    For members who are new to the plan, defined as having a coverage effective date of 90 days or less, documentation must show that the member is currently receiving treatment with the requested drug. Treatment obtained as samples or through a manufacturer's patient assistance program does not qualify as documentation of current treatment.

    Provider Actions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Tepezza (teprotumumab-trbw) under the MassHealth UPPL medical benefit.

    • Benefit: Medical benefit
    • Plan/program: MassHealth UPPL
    • Prior authorization applies; Tepezza is also available under the pharmacy benefit
    Step Therapy

    Glucocorticoid Prerequisite or Exception

    Authorization requires inadequate response, an adverse reaction, or a contraindication to glucocorticoids. An exception may be considered when documentation shows the member is not a corticosteroid candidate or that steroid-sparing therapy is clinically appropriate.

    • Relative contraindications such as obesity or elevated blood glucose may support bypassing corticosteroids when clinically compelling
    • Steroid-sparing therapy may be considered when steroids are effective but the prescriber prefers steroid-free treatment

    Background

    Tepezza (teprotumumab-trbw) is a biologic that targets the insulin-like growth factor-1 receptor. It is indicated for the treatment of thyroid eye disease in adults. The policy addresses use when glucocorticoids are inadequate, not tolerated, contraindicated, or otherwise unsuitable, and considers disease severity and prior response when repeat treatment is requested.

    Definitions

    Thyroid Eye Disease (TED)
    ConditionThyroid eye disease (TED)
    DefinitionA thyroid-associated orbital disease.
    Indication contextTepezza is indicated for the treatment of TED in adults.
    IGF-1 Receptor
    TargetInsulin-like growth factor-1 (IGF-1) receptor
    RoleBiologic target of teprotumumab.
    TherapyTepezza (teprotumumab-trbw) targets the IGF-1 receptor.

    Initial Therapy Criteria

    Standard Tepezza authorization

    Authorization may be granted when all clinical criteria are met.

    Initial or standard authorization

    • Clinical diagnosis and age: Member has a diagnosis of thyroid eye disease and is at least 18 years of age.Age >= 18 years
    • ONE of

      • Prescriber is an endocrinologist.
      • Prescriber is an ophthalmologist.

    Continuation and Repeat-Course Therapy

    Tepezza continuation and repeat-course therapy

    Reauthorization may be granted by a physician for members who have not completed 6 months or 8 doses of treatment; additional courses are reviewed case by case for medical necessity.

    Continuation therapy: Member has not completed 6 months or 8 doses of treatment, or a repeat course is supported by case-by-case medical necessity review.Maximum 8 doses over 6 months for one course of therapy per lifetime

    Repeat-course review considers disease severity, response to prior courses, adherence to prior courses, and failed alternative trials.

    Step Therapy

    StepRequirement
    1Before Tepezza authorization, the member must have inadequate response, an adverse reaction, or a contraindication to glucocorticoids. Documentation that the member is not a candidate for corticosteroids may support bypassing corticosteroid treatment, including certain relative contraindications or clinically appropriate steroid-sparing treatment.

    Quantity Limits

    Tepezza Quantity Limit
    Maximum doses8 doses
    Course duration6 months
    Lifetime limitOne course of therapy per lifetime
    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyTepezza (teprotumumab-trbw) Continuation Therapy
    Policy CodePolicy N/A
    Change TypeMaterial coverage criteria update
    Effective DateJan 4, 202746d
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit clinical rationale for Tepezza instead of Lumvoa and confirm the member has no history of Lumvoa treatment.
    SourceLink
    On This Page
    Coverage CriteriaProvider ActionsBackgroundDefinitionsInitial Therapy CriteriaContinuation and Repeat-Course TherapyStep TherapyQuantity Limits
  1. Earlier teprotumumab treatment may be considered for significant disease when prescribed by an ophthalmologist to help avoid later surgery
  2. Disease-specific symptoms such as proptosis or diplopia may support an exception when steroids would target different symptoms, such as severe inflammation or periorbital edema
  3. Documentation Required

    New-to-Plan Treatment Records

    For members whose coverage effective date is 90 days or less, submit medical records showing that the member is currently receiving the requested drug. This requirement does not apply when the product was obtained as samples or through a manufacturer’s patient assistance program.

    • Applies to members new to the plan with a coverage effective date of less than or equal to 90 days
    • Document current treatment with Tepezza
    Documentation Required

    Clinical Authorization Documentation

    Submit documentation supporting all authorization criteria: thyroid eye disease, age 18 or older, appropriate specialist involvement, glucocorticoid treatment response or exception, rationale for Tepezza over Lumvoa, no prior Lumvoa treatment, and weight-based dosing.

    • Diagnosis: thyroid eye disease
    • Member is ≥18 years of age
    • Prescriber is an endocrinologist or ophthalmologist, or consultation notes from one of these specialists are provided
    • Document inadequate response, adverse reaction, or contraindication to glucocorticoids
    • Provide clinical rationale for Tepezza instead of Lumvoa
    • Document no history of treatment with Lumvoa
    • Provide member weight to support appropriate dosing
    Denial Risk

    Failure to Meet Authorization Criteria

    Authorization may be denied when the member does not meet the required clinical criteria or the submission does not document the requested elements. Denial risks include an unsupported diagnosis, age below 18, missing endocrinology or ophthalmology involvement, failure to address glucocorticoid use or exception criteria, inadequate rationale, prior Lumvoa treatment, or inappropriate dosing.

    • No documented diagnosis of thyroid eye disease
    • Member is under 18 years of age
    • No qualifying endocrinologist or ophthalmologist prescriber or consultation documentation
    • No documented inadequate response, adverse reaction, contraindication, or approved exception to glucocorticoids
    • No clinical rationale for Tepezza instead of Lumvoa
    • History of treatment with Lumvoa
    • Weight or dosing information is missing or dosing is not appropriate
    Billing Rule

    Lifetime Course and Dosing Limit

    Approvals are limited to one course of therapy per lifetime, with a maximum of 8 doses administered over 6 months.

    • Maximum: 8 doses
    • Duration: 6 months
    • Limit: one course per lifetime
    Consult notes from an endocrinologist or ophthalmologist are provided.
  4. ONE of

    • Member has an inadequate response to glucocorticoids.
    • Member has an adverse reaction to glucocorticoids.
    • Member has a contraindication to glucocorticoids.
    • Documentation supports that the member is not a candidate for corticosteroids.

      See Appendix A.

  5. Product selection and treatment history: Clinical rationale is provided for use of Tepezza instead of Lumvoa, and the member has no history of treatment with Lumvoa.
  6. Dosing: Appropriate dosing is requested and the member's weight is provided.Weight required